Trimetazidine-Astrapharm

Release Forms:

The composition 1 tablets:

  • active substance: trimetazidine;
  • 1 tablet contains trimetazidine dihydrochloride 20 mg;
  • excipients: corn starch, mannitol E 421, povidone, talc, magnesium stearate, «СелеКоат™» coating (hypromellose,
    polyethylene glycol (macrogol) 6000, titanium dioxide E 171), dye “Azorubin” (carmoisine) E 122, dye “Yellow West FCF” E 110.

 

30 tablets in a blister, 1 or 2 blisters in a box.

30 tablets in a blister, 1 or 2 blisters in a box.

In adults, trimetazidine is indicated for the symptomatic treatment of stable angina in case of insufficient efficacy or intolerance of first-line antianginal drugs.

Trimetazidine-Astrapharm is administered orally 1 tablet (20 mg) 3 times a day with meals, washed down with 1 glass of water.
The duration of treatment is determined by the doctor depending on the severity and course of the disease.